What is the optimal ventilation strategy in COVID-19, in particular PEEP and the moment of switch to pressure support, in invasively ventilated patients with COVID-19?

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.04301E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2024
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principal Investigator

    dr MJ. prof Schultz MD PhD
  • Research Location

    Netherlands
  • Lead Research Institution

    Amsterdam UMC Locatie AMC
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Patients with coronavirus disease 2019 (COVID-19) can develop severe pneumonia, for which they often require artificial respiration, also known as ventilation. Research into ventilation in intensive care patients in general has already led to measures aimed at preventing damage from the ventilation itself. It remains uncertain whether the same measures should be taken for COVID-19 patients. It is still unclear at what pressure it is best to ventilate, and also whether it is better to allow a patient to breathe spontaneously quickly on the ventilator. Goal The aim of this study is to determine the best pressure level for ventilation and the best time to allow a patient to breathe spontaneously during ventilation. Research design In the first and second waves of the national outbreak of COVID-19 in the Netherlands, two studies, called 'PRactice of VENTilation in COVID-19' (PRoVENT-COVID) and the 'PRactice of Adjunctive Therapies in ICU patients with COVID-19' (PRoAcT-COVID) carried out. Both studies were large, with >1000 patients in each. The data from these two studies will be combined and further supplemented to answer the questions of this new study.